626 related articles for article (PubMed ID: 26841376)
1. Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma.
Dancheva Z; Bochev P; Chaushev B; Yordanova T; Klisarova A
Nucl Med Rev Cent East Eur; 2016; 19(1):22-7. PubMed ID: 26841376
[TBL] [Abstract][Full Text] [Related]
2. Dual-time point
Parghane RV; Basu S
Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
[TBL] [Abstract][Full Text] [Related]
4. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
[TBL] [Abstract][Full Text] [Related]
5. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ
Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of
Kassem TW; Abdelaziz O; Emad-Eldin S
Diagn Interv Imaging; 2017 Oct; 98(10):693-698. PubMed ID: 28734778
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
8. Monitoring bone and soft-tissue tumors after carbon-ion radiotherapy using ¹⁸F-FDG positron emission tomography: a retrospective cohort study.
Yanagawa T; Saito K; Kiyohara H; Ohno T; Nakano T; Takagishi K
Radiat Oncol; 2015 Dec; 10():259. PubMed ID: 26691334
[TBL] [Abstract][Full Text] [Related]
9. Meta-Analysis of the Diagnostic Accuracy of Primary Bone and Soft Tissue Sarcomas by 18F-FDG-PET.
Younis MH; Abu-Hijleh HA; Aldahamsheh OO; Abualruz A; Thalib L
Med Princ Pract; 2020; 29(5):465-472. PubMed ID: 31887730
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing
Chen B; Feng H; Xie J; Li C; Zhang Y; Wang S
BMC Med Imaging; 2020 Jul; 20(1):85. PubMed ID: 32711449
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.
Hahn S; Hecktor J; Grabellus F; Hartung V; Pöppel T; Kimmig R; Forsting M; Antoch G; Heusner TA
Acta Radiol; 2012 Jun; 53(5):518-23. PubMed ID: 22547387
[TBL] [Abstract][Full Text] [Related]
12. Integrated 18F-FDG PET/MRI compared to MRI alone for identification of local recurrences of soft tissue sarcomas: a comparison trial.
Erfanian Y; Grueneisen J; Kirchner J; Wetter A; Podleska LE; Bauer S; Poeppel T; Forsting M; Herrmann K; Umutlu L
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1823-1831. PubMed ID: 28567495
[TBL] [Abstract][Full Text] [Related]
13. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases.
Charest M; Hickeson M; Lisbona R; Novales-Diaz JA; Derbekyan V; Turcotte RE
Eur J Nucl Med Mol Imaging; 2009 Dec; 36(12):1944-51. PubMed ID: 19593561
[TBL] [Abstract][Full Text] [Related]
14. The diagnostic and prognostic value of ¹⁸F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients.
Fuglø HM; Jørgensen SM; Loft A; Hovgaard D; Petersen MM
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1416-24. PubMed ID: 22699526
[TBL] [Abstract][Full Text] [Related]
15. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
Li DL; Xu YK; Wang QS; Wu HB; Li HS
Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
[TBL] [Abstract][Full Text] [Related]
16. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
17. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
[TBL] [Abstract][Full Text] [Related]
18. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas.
Garcia R; Kim EE; Wong FC; Korkmaz M; Wong WH; Yang DJ; Podoloff DA
J Nucl Med; 1996 Sep; 37(9):1476-9. PubMed ID: 8790197
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]